Annovis Bio Inc (NYSE:ANVS) — Market Cap & Net Worth
Market Cap & Net Worth: Annovis Bio Inc (ANVS)
Annovis Bio Inc (NYSE:ANVS) has a market capitalization of $60.63 Million ($60.63 Million) as of June 22, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #21186 globally and #4700 in its home market, demonstrating a 1.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Annovis Bio Inc's stock price $1.75 by its total outstanding shares 34646868 (34.65 Million). Review ANVS total liabilities to assess the company's total debt and financial obligations.
Annovis Bio Inc Market Cap History: 2020 to 2026
Annovis Bio Inc's market capitalization history from 2020 to 2026. Data shows change from $261.24 Million to $60.63 Million (-23.38% CAGR).
Annovis Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Annovis Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANVS by Market Capitalization
Companies near Annovis Bio Inc in the global market cap rankings as of June 22, 2026.
Key companies related to Annovis Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Annovis Bio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Annovis Bio Inc's market cap moved from $261.24 Million to $ 60.63 Million, with a yearly change of -23.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $60.63 Million | -49.42% |
| 2025 | $119.88 Million | -31.21% |
| 2024 | $174.27 Million | -73.10% |
| 2023 | $647.90 Million | +39.24% |
| 2022 | $465.31 Million | -23.61% |
| 2021 | $609.09 Million | +133.16% |
| 2020 | $261.24 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Annovis Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.63 Million USD |
| MoneyControl | $60.63 Million USD |
| MarketWatch | $60.63 Million USD |
| marketcap.company | $60.63 Million USD |
| Reuters | $60.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more